03:34 PM EST, 01/17/2025 (MT Newswires) -- Revance Therapeutics ( RVNC ) climbed almost 12% on Friday, after saying privately-held suitor Crown Laboratories raised its buyout offer for the neuromodulator maker to $3.65 per share.

Based on its 104.4 million outstanding shares, the revised offer - which is set to expire at 4:10 p.m. ET on Friday - comes to an aggregate value of around $381.1 million overall.

The Revance board of directors was evaluating the Crown offer, according to a regulatory filing by the company Friday morning.

Crown earlier this week said it was extending its tender offer for Revance until Jan. 28 after shareholders owning less than 4% of its outstanding stock had tendered their shares at the previous price of $3.10 each by the close of business on Jan. 10. The deal had required at least a majority of Revance shareholders to tender their stock for the transaction to go through.

Price: 3.66, Change: +0.39, Percent Change: +11.77